




IRB 21257: Evaluation of TAK-981 and TAK-981 Combinations Following Intratumoral CIVO® Microdosing in Patients with Head and Neck Cancer

IRB 22805: A Phase 0 Master Protocol Using the CIVO Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients with Solid Tumors

03.29.2021



CROSS-DISEASE TRIALS:
 IRB 00021902: IRB# 19992
EAY131
(MATCH)

Key

- Open for Enrollment
- In Development
- Enrollment on Hold